Form 8-K - Current report:
SEC Accession No. 0000950170-23-030542
Filing Date
2023-06-29
Accepted
2023-06-29 08:31:31
Documents
12
Period of Report
2023-06-28
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20230628.htm   iXBRL 8-K 95101
  Complete submission text file 0000950170-23-030542.txt   219362

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20230628_pre.xml EX-101.PRE 11450
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20230628_lab.xml EX-101.LAB 14907
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20230628.xsd EX-101.SCH 2464
6 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20230628_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 231054400
SIC: 2836 Biological Products, (No Diagnostic Substances)